Cargando…
IOX1 impedes host inflammation in imiquimod-triggered psoriasis
Psoriasis is a chronic autoimmune disease with an unknown etiology and highly limited treatment strategies. The drugs currently used in the treatment of psoriasis are rarely recommended for long-term use owing to the serious side effects. Although different targets have been identified for controlli...
Autores principales: | Shin, Joo Eun, Lee, Su Jin, Gharbi, Amal, Jung, In Duk, Park, Yeong Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632842/ https://www.ncbi.nlm.nih.gov/pubmed/34877426 http://dx.doi.org/10.1016/j.heliyon.2021.e08433 |
Ejemplares similares
-
IOX1 activity as sepsis therapy and an antibiotic against multidrug-resistant bacteria
por: Lee, Su Jin, et al.
Publicado: (2021) -
Therapeutic Effects of Erythroid Differentiation Regulator 1 on Imiquimod-Induced Psoriasis-Like Skin Inflammation
por: Kim, Kyung Eun, et al.
Publicado: (2016) -
Resveratrol Ameliorates Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice
por: Kjær, Thomas Nordstrøm, et al.
Publicado: (2015) -
Anoctamin1 Induces Hyperproliferation of HaCaT Keratinocytes and Triggers Imiquimod-Induced Psoriasis-Like Skin Injury in Mice
por: Choi, Mi Ran, et al.
Publicado: (2021) -
The Protective Role of pVHL in Imiquimod-Induced Psoriasis-like Skin Inflammation
por: Martínez-Torres, Isaí, et al.
Publicado: (2022)